R7V therapeutic antibody program (URRMA Biopharma/Dyax)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameR7V therapeutic antibody program (URRMA Biopharma/Dyax)
Drug Alias Nameanti-R7V monoclonal antibody (Dyax/URRMA)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionImmunostimulantsR7V inhibitors
TargetsBeta-2-microglobulin
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUrrma BiopharmaDyax Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUrrma BiopharmaDyax Corp
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A